CA3083734A1 - Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof - Google Patents

Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof Download PDF

Info

Publication number
CA3083734A1
CA3083734A1 CA3083734A CA3083734A CA3083734A1 CA 3083734 A1 CA3083734 A1 CA 3083734A1 CA 3083734 A CA3083734 A CA 3083734A CA 3083734 A CA3083734 A CA 3083734A CA 3083734 A1 CA3083734 A1 CA 3083734A1
Authority
CA
Canada
Prior art keywords
formula
methoxyisochroman
ethyl
compound
carboxylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3083734A
Other languages
English (en)
French (fr)
Inventor
Ilpo Laitinen
Mikko Leskinen
Mikko Makela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of CA3083734A1 publication Critical patent/CA3083734A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Epoxy Resins (AREA)
  • Detergent Compositions (AREA)
CA3083734A 2017-12-01 2018-11-30 Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof Pending CA3083734A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20176085 2017-12-01
FI20176085 2017-12-01
PCT/FI2018/050864 WO2019106238A1 (en) 2017-12-01 2018-11-30 Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof

Publications (1)

Publication Number Publication Date
CA3083734A1 true CA3083734A1 (en) 2019-06-06

Family

ID=64746580

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3083734A Pending CA3083734A1 (en) 2017-12-01 2018-11-30 Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof

Country Status (19)

Country Link
US (1) US11352346B2 (enExample)
EP (1) EP3717476B1 (enExample)
JP (1) JP7339946B2 (enExample)
KR (1) KR102718536B1 (enExample)
CN (1) CN111630049B (enExample)
AU (1) AU2018376872B2 (enExample)
BR (1) BR112020010617A2 (enExample)
CA (1) CA3083734A1 (enExample)
DK (1) DK3717476T3 (enExample)
ES (1) ES2927193T3 (enExample)
HR (1) HRP20221247T1 (enExample)
HU (1) HUE059849T2 (enExample)
IL (1) IL274931B2 (enExample)
LT (1) LT3717476T (enExample)
PL (1) PL3717476T3 (enExample)
PT (1) PT3717476T (enExample)
SI (1) SI3717476T1 (enExample)
WO (1) WO2019106238A1 (enExample)
ZA (1) ZA202003981B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112020003658T5 (de) 2019-07-31 2022-05-19 Hyundai Motor Company Sdn-basiertes eindringungsverhinderungsverfahren für ein fahrzeuginternesnetz und system, das dieses verfahren verwendet
KR20230159515A (ko) * 2021-03-19 2023-11-21 오리온 코포레이션 타시피미딘 제형 및 이의 용도
JP2025502480A (ja) * 2022-01-24 2025-01-24 オリオン コーポレーション イソクロマン－イミダゾール構造のアルファ－２ａアドレナリン受容体アゴニストの新規な硫酸塩形
WO2023148431A1 (en) 2022-02-04 2023-08-10 Orion Corporation Novel salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist
JP2025531623A (ja) 2022-09-28 2025-09-22 オリオン コーポレーション タシピミジンおよびｃｙｐ２ｄ６阻害薬の併用療法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410562B1 (en) * 1998-12-18 2002-06-25 Eli Lilly And Company Hypoglycemic imidazoline compounds
AR090557A1 (es) * 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2

Also Published As

Publication number Publication date
US11352346B2 (en) 2022-06-07
HUE059849T2 (hu) 2023-01-28
US20200308152A1 (en) 2020-10-01
JP7339946B2 (ja) 2023-09-06
RU2020121597A3 (enExample) 2022-01-04
EP3717476B1 (en) 2022-08-03
LT3717476T (lt) 2022-09-26
AU2018376872B2 (en) 2023-12-07
CN111630049A (zh) 2020-09-04
IL274931A (en) 2020-07-30
ES2927193T3 (es) 2022-11-03
HRP20221247T1 (hr) 2022-12-09
EP3717476A1 (en) 2020-10-07
BR112020010617A2 (pt) 2020-11-10
RU2020121597A (ru) 2022-01-04
KR102718536B1 (ko) 2024-10-21
PT3717476T (pt) 2022-08-23
SI3717476T1 (sl) 2022-10-28
IL274931B2 (en) 2023-11-01
WO2019106238A1 (en) 2019-06-06
JP2021504418A (ja) 2021-02-15
AU2018376872A1 (en) 2020-07-16
PL3717476T3 (pl) 2022-11-21
IL274931B1 (en) 2023-07-01
KR20200095519A (ko) 2020-08-10
CN111630049B (zh) 2023-06-20
DK3717476T3 (da) 2022-09-05
ZA202003981B (en) 2021-07-28

Similar Documents

Publication Publication Date Title
EP3717476B1 (en) Process for the preparation of 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1h-imidazole and the hydrogensulfate salt thereof
CA2954167C (en) Process for the preparation of 4-alkoxy-3-hydroxypicolinic acids
JP6268093B2 (ja) 縮合複素環誘導体の製造方法およびその製造中間体
US10689349B2 (en) Method for producing intermediate of biotin and method for producing biotin
EP3668857B1 (en) Processes for the preparation of niraparib and intermediates thereof
KR20200099548A (ko) 구충제 4-아미노-퀴놀린-3-카르복스아미드 유도체를 제조하는 방법
EP3442944B1 (en) Process for the preparation of 4-aminoindane derivatives and related aminoindane amides
WO2018187717A1 (en) Continuous flow synthesis of ibuprofen
US20200002291A1 (en) Benzimidazole Compound and Preparation Method Thereof
JP2025026621A (ja) シス－（－）－フロシノピペリドールの製造方法
WO2012127483A1 (en) Processes for the preparation of intermediates of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide
RU2791469C2 (ru) Способ получения 2-(5-метоксиизохроман-1-ил)-4,5-дигидро-1h-имидазола и его гидросульфата
US12522554B2 (en) Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist
KR101079065B1 (ko) 치환된 이미다졸 유도체를 제조하기 위한 방법 및 공정에서사용된 중간체
SK9892003A3 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
JP2018108978A (ja) ビオチンの中間体の製造方法、およびビオチンの製造方法
CN110577520B (zh) 一种6-硝基-4-取代氨基喹唑啉衍生物的制备方法
JP6660393B2 (ja) ４−シアノピペリジン塩酸塩を調製する方法
JP7774448B2 (ja) Ｂｔｋ阻害剤を調製するためのプロセス及び中間体
CN107778307B (zh) 一种中枢性α2肾上腺素受体激动剂的制备方法
EP2462144B1 (en) PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
HK1230509A1 (en) Clomiphene synthesis using a single solvent

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231116

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241118

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241118

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241118

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241125

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250403

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250716

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250716

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251110

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251110

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260519

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260519